Platelets and Cancer: Implications for Antiangiogenic Therapy

Mohit Trikha; Marian T. Nakada

doi:10.1055/s-2002-20563

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2002; 28(1): 39-44
DOI: 10.1055/s-2002-20563

Platelets and Cancer: Implications for Antiangiogenic Therapy

Mohit Trikha, Marian T. Nakada

Department of Oncology Research, Centocor, Malvern, Pennsylvania

Abstract

ABSTRACT

Thromboembolism is one of the most common causes of death in cancer patients. Among the most frequent thrombotic complications in patients with cancer are disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, and thrombocytosis. Clearly, these complications arise as tumor cells interact with almost all components of the hemostatic system including platelets. Platelets participate in tumor progression by contributing to the metastatic cascade, protecting tumor cells from immune surveillance, regulating tumor cell invasion, and angiogenesis. Platelets contain one of the largest stores of angiogenic and mitogenic factors and the tumor vasculature is leaky, which allows platelets to come in contact with the tumor and deposit multiple angiogenic factors including vascular endothelial growth factor (VEGF) and thrombin to tumor cells, which in turn contributes to tumor progression. This article reviews the recent literature on how platelets contribute to tumor growth, angiogenesis, and metastasis.

KEYWORD

Platelets - cancer - metastasis - angiogenesis - integrins

Full Text

References

REFERENCES

1 Loreto M F, De Martinis M, Corsi M P, Modesti M, Ginaldi L. Coagulation and cancer: implications for diagnosis and management. Pathol Oncol Res . 2000; 6 301-312
2 Hejna M, Raderer M, Zielinski C C. Inhibition of metastases by anticoagulants. J Natl Cancer Inst . 1999; 91 22-36
3 Tang D G, Honn K V. Adhesion molecules and tumor metastasis: an update. Invasion Metastasis . 1994; 14 109-122
4 Steinert B W, Tang D G, Grossi I M, Umbarger L A, Honn K V. Studies on the role of platelet eicosanoid metabolism and integrin α_IIbβ₃ in tumor-cell-induced platelet aggregation. Int J Cancer . 1993; 54 92-101
5 Timar J, Chopra H, Rong X. Calcium channel blocker treatment of tumor cells induces alterations in the cytoskeleton, mobility of the integrin α_IIbβ₃ and tumor-cell-induced platelet aggregation. J Cancer Res Clin Oncol . 1992; 118 425-434
6 Tang D G, Grossi I M, Tang K Q. Inhibition of TPA and 12(S)-HETE-stimulated tumor cell adhesion by prostacyclin and its stable analogs: rationale for their antimetastatic effects. Int J Cancer . 1995; 60 418-425
7 Jordan R E, Wagner C L, Mascelli M A. Preclinical development of c7E3 Fab; a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of Gp IIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. In: Horton MA, ed. Adhesion Receptors as Therapeutic Targets New York: CRC Press 1996: 281-305
8 Mascelli M A, Lance E T, Damaraju L. The pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GpIIb/IIIa receptor blockade. Circulation . 1998; 97 1680-1688
9 Lincoff A M, Tcheng J E, Califf R M, for the EPILOG Investigators. Sustained suppression of ischemic complications of coronary intervention by platelet GpIIb/IIIa blockade with abciximab. One year outcome of the EPILOG trial. Circulation . 1999; 99 1951-1958
10 Topol E J, Ferguson J J, Weisman H F, for the EPIC Investigators. Long-term prevention from myocardial ischemic events in a randomized trial of brief integrin β₃ blockade with percutaneous coronary intervention. JAMA . 1997; 278 479-484
11 Felding-Habermann B, O'Toole T E, Smith J W. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA . 2001; 98 1853-1858
12 Nierodzik M L, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost . 1995; 74 282-290
13 Zucchella M, Dezza L, Pacchiarini L. Human tumor cells cultured ``in vitro'' activate platelet function by producing ADP or thrombin. Haematologica . 1989; 74 541-545
14 Seto S-I, Onodera H, Kaido T. Tissue factor expression in human colorectal carcinoma. Cancer . 2000; 88 295-301
15 Ogiichi T, Yutaka H, Nakamura S. Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation. J Neurooncol . 2000; 46 1-9
16 Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer . 2000; 83 164-170
17 Nierodzik M L, Plotkin A, Kajumo F, Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest . 1991; 87 229-236
18 Nierodzik M L, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res . 1992; 52 3267-3272
19 Butenas S, Cawthern K, Veer C. Antiplatelet agents in tissue factor-induced blood coagulation. Blood . 2001; 97 2314-2322
20 Amirkhosravi A, Amaya M, Siddiqui F. Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis. Platelets . 1999; 10 285-292
21 Pinedo H M, Verheul H MW, D'Amato R J, Folkman J. Involvement of platelets in tumour angiogenesis?. Lancet . 1998; 352 1775-1777
22 Heyn Adu P, Lötter M G, Badenhorst P N. Kinetics, distribution and site of destruction of ¹¹¹indium-labelled human platelets. Br J Haematol . 1980; 44 269-280
23 Chronos N, Marciniak S J, Nakada M T. Binding specificity and associated effects of platelet GpIIb/IIIa inhibitors. Eur Heart J . 1999; 1(Suppl E) E11-E17
24 Möhle R, Green D, Moore M AS, Nachman R L, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA . 1997; 94 663-668
25 Maloney J P, Silliman C C, Ambruso D R. In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol . 1995; 275 H1054-H1061
26 Jelkman W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem . 2001; 47 617-623
27 Verheul H MW, Jorna A S, Hoekman K. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood . 2000; 96 4216-4221
28 Trikha M, Zhou Z, Jordan R, Nakada M T. ReoPro and m7E3 F(ab′)₂ inhibit β3 integrin mediated tumor growth and angiogenesis. Proc Am Assoc Cancer Res . 2000; 42 824-824 Abst 3678
29 Cox G, Walker R A, Andi A, Steward W P, O'Byrne K J. Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer . 2000; 29 169-177
30 Pedersen L M, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J . 1996; 9 1826-1830
31 Gücer F, Moser F, Tamussino K. Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol Oncol . 1998; 70 210-214
32 Salgado R, Vermeulen P B, Benoy I. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels in advanced cancer patients. Br J Cancer . 1999; 80 892-897
33 Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem . 2000; 275 1521-1524
34 Nieswandt B, Hafner M, Echtendacher B, Mannel D N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res . 1999; 59 1295-1300
35 Borsig L, Wong R, Feramisco J. Heparin and cancer revisited. Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA . 2001; 98 3352-3357
36 Belloc C, Lu H, Soria C. The effect of platelets on invasiveness and protease production of human mammary tumor cells. Int J Cancer . 1995; 60 413-417
37 Cohen S A, Trikha M, Mascelli M A. Potential future clinical applications for the GpIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications. Pathol Oncol Res . 2000; 6 163-174
38 Coller B S. Anti-GpIIb/IIIa drugs: current strategies and future directions. Thromb Haemost . 2001; 86 427-443
39 Klement G, Baruchel S, Rak J. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induce tumor regression without overt toxicity. J Clin Invest . 2000; 105 1045-1047
40 Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost . 2001; 86 23-33